Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206511) titled 'Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study' on Sept. 25.
Study Type: Observational [Patient Registry]
Primary Sponsor: Shanghai Zhongshan Hospital
Condition:
Unresectable Hepatocellular Carcinom
Recruitment Status: Not recruiting
Date of First Enrollment: October 9, 2025
Target Sample Size: 278
To know more, visit https://clinicaltrials.gov/study/NCT07206511
Published by HT Digital Content Services wit...